



## Press Release

February 27, 2017

Astellas Pharma Inc.  
Kyowa Pharmaceutical Industry Co., Ltd.

### **Kyowa and Astellas enter into an Agreement for Exclusive Distribution and Promotion of Extended-Release Tablets of Quetiapine Fumarate in Japan**

Kyowa Pharmaceutical Industry Co., Ltd. (Head office: Yodogawa-ku, Osaka City, President and Representative Director: Ray Tsunoda, hereinafter called “Kyowa”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the companies have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan. Astellas submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder.

When Astellas obtains an approval for the new drug application of extended-release tablets of quetiapine fumarate, based on the agreement, Kyowa will exclusively distribute and promote the products in Japan.

###

#### **About Kyowa Pharma**

Founded in 1954, Kyowa Pharmaceutical Industry Co., Ltd. is a pharmaceutical company developing and manufacturing Branded & Generic pharmaceutical products for patients in the Japanese Market. With sales of JPY 25 billion for the fiscal year ended March 2016, Kyowa is amongst the fastest growing pharmaceutical companies in Japan, a market leader in the Central Nervous System - Neurology space and has strong presence in Cardiovascular, Gastroenterology and Injectables therapy segments. The company covers 94% of the 1,400 psychiatric hospitals in Japan. Kyowa enjoys strong brand equity in the psychiatric and neurological therapy segments, well known for its high quality pharmaceutical product portfolio under the “Kyowa AMEL” brand franchise. Kyowa is a Japanese subsidiary of Lupin Limited. For more information, please visit our website at <http://www.kyowayakuhin.co.jp>

**About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at [www.astellas.com/en](http://www.astellas.com/en).

For further information or queries please contact –  
Kyowa Pharmaceutical Industry Co., Ltd.  
President Office  
TEL; +81-6-6308-3320 FAX: +81-6-6308-7140

About Astellas Pharma Inc.  
Corporate Communications  
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473